Milestone Pharmaceuticals Inc. Paid-in-Kind Interest
Milestone Pharmaceuticals Inc. (MIST) reported Paid-in-Kind Interest of $1.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. paid-in-kind interest for the quarter ending 2026-06-30 was $897.00K, a 6.15% increase year-over-year.
- Milestone Pharmaceuticals Inc. paid-in-kind interest for the quarter ending 2026-03-31 was $884.00K, a 6.12% increase year-over-year.
- Milestone Pharmaceuticals Inc. paid-in-kind interest for the quarter ending 2025-12-31 was $870.00K, a 5.97% increase year-over-year.
- Milestone Pharmaceuticals Inc. paid-in-kind interest for the quarter ending 2025-09-30 was $859.00K, a 6.31% increase year-over-year.
- Milestone Pharmaceuticals Inc. paid-in-kind interest for fiscal 2025 was $3.41M, a 6.14% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. paid-in-kind interest for fiscal 2024 was $3.21M, a 38.96% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. paid-in-kind interest for fiscal 2023 was $2.31M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $897.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.78M 10-Q · filed 2026-08-12 | $2.65M derived: sum of 3 quarters · filed 2026-08-12 | $3.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $884.00K 10-Q · filed 2026-05-13 | $1.75M derived: sum of 2 quarters · filed 2026-05-13 | $2.61M derived: sum of 3 quarters · filed 2026-05-13 | $3.46M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.73M derived: sum of 2 quarters · filed 2026-03-20 | $2.57M derived: sum of 3 quarters · filed 2026-08-12 | $3.41M 10-K · filed 2026-03-20 |
| 2025-09-30 | $859.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.70M derived: sum of 2 quarters · filed 2026-08-12 | $2.54M 10-Q · filed 2025-11-12 | $3.36M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $845.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.68M 10-Q · filed 2026-08-12 | $2.50M derived: sum of 3 quarters · filed 2026-08-12 | $3.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $833.00K 10-Q · filed 2026-05-13 | $1.65M derived: sum of 2 quarters · filed 2026-05-13 | $2.46M derived: sum of 3 quarters · filed 2026-05-13 | $3.26M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $821.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.63M derived: sum of 2 quarters · filed 2026-03-20 | $2.42M derived: sum of 3 quarters · filed 2026-03-20 | $3.21M 10-K · filed 2026-03-20 |
| 2024-09-30 | $808.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.60M derived: sum of 2 quarters · filed 2025-11-12 | $2.39M 10-Q · filed 2025-11-12 | $3.16M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $796.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.58M 10-Q · filed 2025-08-12 | $2.35M derived: sum of 3 quarters · filed 2025-08-12 | $3.12M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $785.00K 10-Q · filed 2025-05-14 | $1.56M derived: sum of 2 quarters · filed 2025-05-14 | $2.32M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $773.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.53M derived: sum of 2 quarters · filed 2025-03-13 | $2.31M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $762.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.54M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $775.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |